VIDA focuses on accelerating respiratory clinical trials through data-driven clinical trial methodologies, including optimized imaging operations and data insights.

VIDA

Rittenhouse Ventures is a Philadelphia-based venture capital firm that focuses on early-stage investments in technology businesses, providing expertise and financial support to entrepreneurs.

Rittenhouse Ventures

VIDA | 5,381 followers on LinkedIn. Modernizing Lung and Respiratory Care | VIDA is a clinical imaging intelligence company that is accelerating the approval and adoption of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, VIDA’s solution is helping biopharma sponsors save millions in drug development costs.

Corporate Board Director, ResMed, Outset Medical … Former CEO

Karen Drexler

Sandra Stapleton

Marketing at VIDA Diagnostics

Marcel Nienhuis

Director of Human Resources at VIDA

Shanna Lynnes

We are honored to welcome Wisia Wedzicha, MD, PhD, an expert in COPD, as our next webinar guest! Dr. Wedzicha will dive into BEACON, a unique study uncovering the earliest signs of COPD in young smokers with normal spirometry 🫁. The BEACON study was featured on the cover of the Blue Journal (AJRCCM) 📖 earlier this year. 👉 Save your spot now: https://lnkd.in/gNu9b8Rm #COPD #BEACON #VIDAPresents #Webinar

New findings from Brightling et al. on the relationship between mucus plugging and air trapping: "A reduction in mucus plugging with tezepelumab treatment was correlated with a spatially-associated improvement in air trapping index." https://hubs.la/Q02YxKQ50 Authors: chris brightling , Å Hellqvist, S Diver, C Porsbjerg, E Israel, John D Newell , Sam Peterson , JM Sepena, AW Lindsley, A Megally, Lars Haug Nordenmark British Thoracic Society (BTS)

For our US employees, today is the day #VIDAVotes ! 🇺🇸 All employees are granted a 4-hour window today, ensuring ample time to exercise our right to vote. See you at the polls! #gotv #vote #voting #electionday #teamVIDA

An excellent editorial by Cara Flynn and Chris Brightling: "Picture this: the future of imaging biomarkers in COPD." https://hubs.la/Q02W3MPq0 "In the near future, artificial intelligence, which is advancing rapidly in other areas of imaging, could be more widely adopted forCOPD imaging."

November is #Alpha1Awareness Month! Join us in raising awareness for Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can lead to serious lung and liver diseases. We are committed to help accelerate new therapies to these patients. ICYMI, here's our webinar with Dr. Barjaktarevic on the topic. https://hubs.la/Q02Wy3vZ0 #AATD

Happy Halloween 🎃 from VIDA! May your evening be full of treats. 👻 🕸️🕷️ #HappyHalloween #TeamVIDA

Can CT help find 🕵🏽♂️ those elusive PRISm* patients? Lukhumaidze and colleagues just shared some promising results that point to "yes." They examined a wide range of quantitative imaging biomarkers and found "reduced lung volumes, elevated HAA%, and elevated GGO/reticulation patterns are associated with stable PRISm." More here: https://hubs.la/Q02W7Xtt0 Authors: Leila Lukhumaidze, MSc, James C. Hogg, MD, PhD, Jean Bourbeau, MD, Wan C. Tan, MD, Miranda Kirby, PhD *PRISm stands for "Preserved Ratio Impaired Spirometry." It occurs when a person has a simultaneous reduction in both FEV1 and FVC, resulting in a preserved FEV1/FVC ratio of 0.70 or higher (thereby not meeting a common diagnostic criteria for COPD, despite compromised lung function). #PRISm #COPD #digitalbiomarkers #QCT #HAA #LAA #TLV #GGO

New research on vascular chest CT biomarkers from the #CanCOLD group: "Resting pulmonary vascular volumes (TVV) and DLCO were associated with Vo2peak. These results suggest that the association of pulmonary vascular structure/function with Vo2peak may be important across the continuum of health and disease." Authors: Sophie É. Collins, PhD, Miranda Kirby , PhD, Benjamin M. Smith, MD, FRCPC, Wan Tan, MD, Jean Bourbeau, MD , Stephanie Thompson, MD, PhD, Sean van Diepen, MD, Dennis Jensen, PhD, Sanja Stanojevic, PhD, Michael Stickland, PhD #COPD #TVV #BV5 #BV10 #DigitalBiomarkers American College of Chest Physicians https://hubs.la/Q02W06Yx0

ICYMI, Rachel Eddy , PhD recently appeared on the American Lung Association 's Lungcast podcast. She gives an excellent overview of AI applications in quantitative lung imaging, including airway remodeling biomarkers, fibrosis scoring, mucus analysis, dysanapsis, xenon MRI, micro CT and more. Check it out here: https://hubs.la/Q02SpW3j0 #AI #XenonMRI #digitalbiomarkers #asthma #ILD #COPD #mucus #microCT #fibrosis #QCT

Going to #CHEST24 this week? Be sure to check out the poster from Stalker, G. et al. on air trapping and GGO in acute COVID as a predictor for Long COVID. The presentation is Oct 8 1:45p-2:30p. https://hubs.la/Q02R151s0 By the way, we spoke with Dr. Comellas about the utility of quantitative imaging in Long COVID. Highlights of that conversation: https://hubs.la/Q02R1jNR0 #CHEST2024 #AirTrapping #vDPM #COVID #LongCOVID

Metric
Company Name	VIDA	Rittenhouse Ventures
Symbol
MSH ID	AI:VIDALUNG	COM:RITTENHOUSEVENTURES
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance
Industry	Medical Technology	Venture Capital
Country	US	US
Stage	Venture Round
Employee Count
Website	vidalung.ai	rittenhouseventures.com
LinkedIn	vidalung	rittenhousevc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	4.44K
Web Traffic Growth	-0.76
Valuation
Raised Capital	10.82M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VIDA

AI:VIDALUNG

VIDA

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue